Cargando…

Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States

PURPOSE: Patients receiving treatment for acromegaly often experience significant associated comorbidities for which they are prescribed additional medications. We aimed to determine the real-world prevalence of comorbidities and concomitant medications in patients with acromegaly, and to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleseriu, Maria, Barkan, Ariel, del Pilar Schneider, Maria, Darhi, Yannis, de Pierrefeu, Amicie, Ribeiro-Oliveira, Antonio, Petersenn, Stephan, Neggers, Sebastian, Melmed, Shlomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894179/ https://www.ncbi.nlm.nih.gov/pubmed/34973139 http://dx.doi.org/10.1007/s11102-021-01198-5

Ejemplares similares

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis
por: Fleseriu, Maria, et al.
Publicado: (2023)

Use of Oral Concomitant Medications in Patients With Acromegaly
por: Petersenn, Stephan, et al.
Publicado: (2021)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study
por: Giustina, Andrea, et al.
Publicado: (2019)

Molecular targets in acromegaly
por: Labadzhyan, Artak, et al.
Publicado: (2022)

Biochemical diagnosis of acromegaly without a typical clinical phenotype: what are the concerns?
por: Ribeiro-Oliveira, Antonio, et al.
Publicado: (2017)

Medical management of Cushing’s disease: what is the future?
por: Fleseriu, Maria, et al.
Publicado: (2012)

New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
por: Fleseriu, Maria, et al.
Publicado: (2013)

SAGIT(®): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study
por: Giustina, Andrea, et al.
Publicado: (2015)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients
por: Bhanot, Sanjay, et al.
Publicado: (2022)

Updates in Diagnosis and Treatment of Acromegaly
por: Zahr, Roula, et al.
Publicado: (2018)

Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly
por: Langlois, Fabienne, et al.
Publicado: (2020)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

Clinical, quality of life, and economic value of acromegaly disease control
por: Ben-Shlomo, A., et al.
Publicado: (2011)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Pregnancy and acromegaly
por: Muhammad, Ammar, et al.
Publicado: (2016)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

Individualized acromegaly treatment: Is stereotactic radiation therapy changing the paradigm?
por: Liu, Winnie, et al.
Publicado: (2022)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences
por: Plunkett, Cynthia, et al.
Publicado: (2015)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases
por: Burton, Tanya, et al.
Publicado: (2012)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
por: Fleseriu, Maria
Publicado: (2010)

Gene expression signature in adipose tissue of acromegaly patients
por: Hochberg, Irit, et al.
Publicado: (2014)

Gene Expression Signature in Adipose Tissue of Acromegaly Patients
por: Hochberg, Irit, et al.
Publicado: (2015)

Prevalence of Comorbidities among Patients with Acromegaly
por: Khan, Sajjad Ali, et al.
Publicado: (2021)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

A Consensus Statement on acromegaly therapeutic outcomes
por: Melmed, Shlomo, et al.
Publicado: (2018)

Challenges in the diagnosis and management of acromegaly: a focus on comorbidities
por: Abreu, Alin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nqgnir4isbkl467erkgfn30s3r